ESMO 2023 | Sacituzumab govitecan plus enfortumab vedotin for treatment of advanced urothelial cancer

Bradley A. McGregor, MD, Dana Farber Cancer Institute, Boston, MA, provides an overview of the Phase I DAD (NCT04724018) trial, the first trial in any malignancy to show that two antibody-drug conjugates (ADCs) can be given together. The trial tests sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for the treatment of urothelial cancer in a cohort reflective of the real-world setting. Due to the need for G-CSF support in the maximum dose, a lower dose was decided during the trial. No new toxicities were found and although treatment of some patients is still ongoing, outcomes are promising in terms of generating future treatments. Follow-up trials will see the integration of this treatment with immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.